Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment

Triple-negative breast cancer (TNBC) shows limited therapeutic efficacy. PARP inhibitor has been approved to treat advanced BRCA-mutant breast cancer but shows high resistance. Therefore, the development of new therapeutics that sensitize TNBC irrespective of BRCA status is urgently needed. The nedd...

Descripción completa

Detalles Bibliográficos
Autores principales: Misra, Shrilekha, Zhang, Xiaoli, Wani, Nissar Ahmad, Sizemore, Steven, Ray, Alo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055543/
https://www.ncbi.nlm.nih.gov/pubmed/32166000
http://dx.doi.org/10.18632/oncotarget.27485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055543/
https://www.ncbi.nlm.nih.gov/pubmed/32166000
http://dx.doi.org/10.18632/oncotarget.27485

Ejemplares similares